Dataset Information


Genome-Edited T Cell Therapies.

ABSTRACT: PURPOSE OF REVIEW:Alternative approaches to conventional drug-based cancer treatments have seen T cell therapies deployed more widely over the last decade. This is largely due to their ability to target and kill specific cell types based on receptor recognition. Introduction of recombinant T cell receptors (TCRs) using viral vectors and HLA-independent T cell therapies using chimeric antigen receptors (CARs) are discussed. This article reviews the tools used for genome editing, with particular emphasis on the applications of site-specific DNA nuclease mediated editing for T cell therapies. RECENT FINDINGS:Genetic engineering of T cells using TCRs and CARs with redirected antigen-targeting specificity has resulted in clinical success of several immunotherapies. In conjunction, the application of genome editing technologies has resulted in the generation of HLA-independent universal T cells for allogeneic transplantation, improved T cell sustainability through knockout of the checkpoint inhibitor, programmed cell death protein-1 (PD-1), and has shown efficacy as an antiviral therapy through direct targeting of viral genomic sequences and entry receptors. SUMMARY:The combined use of engineered antigen-targeting moieties and innovative genome editing technologies have recently shown success in a small number of clinical trials targeting HIV and hematological malignancies and are now being incorporated into existing strategies for other immunotherapies.


PROVIDER: S-EPMC5445182 | BioStudies | 2017-01-01

REPOSITORIES: biostudies

Similar Datasets

2009-01-01 | S-EPMC5548385 | BioStudies
2018-01-01 | S-EPMC5780198 | BioStudies
2020-01-01 | S-EPMC7407663 | BioStudies
2019-01-01 | S-EPMC7027847 | BioStudies
1000-01-01 | S-EPMC4910751 | BioStudies
2019-01-01 | S-EPMC6872726 | BioStudies
2019-01-01 | S-EPMC6611213 | BioStudies
2014-01-01 | S-EPMC3880964 | BioStudies
1000-01-01 | S-EPMC6233129 | BioStudies
2019-01-01 | S-EPMC6891203 | BioStudies